Physician profile
Kaveh Ehsanipoor
NPI 1821037706
$76,114.73
in general payments reported to CMS, 2019-2025
66 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $12K · 2021: $14K · 2022: $1,361 · 2023: $1,840 · 2024: $1,994 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,405 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,405.34 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34,504.62 | 2019-2025 | Tepezza, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $31,903.69 | 2019-2024 | Farxiga, Airsupra, Evusheld |
| Lilly USA, LLC | $1,487.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,092.02 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Mannkind Corporation | $571.65 | 2019-2023 | Afrezza |
| Sanofi-Aventis U.S. LLC | $556.31 | 2019-2023 | |
| Radius Health, INC. | $464.85 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $362.33 | 2021-2023 | Tepezza |
| Abbvie INC. | $294.39 | 2019-2024 | |
| Dexcom, INC. | $259.96 | 2019-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.12 | 2019-2024 | Jardiance |
| Lundbeck LLC | $245.94 | 2024-2025 | Vyepti, Rexulti |
| Janssen Pharmaceuticals, INC | $234.22 | 2019-2024 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $207.18 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $206.91 | 2022-2024 | Quviviq |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaveh Ehsanipoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.